Tumor treating field arrays increased surface dose during photon radiotherapy
Tumor treating field arrays caused substantial surface dose enhancement and measurable dose attenuation during 6-megavolt photon irradiation.
Tumor treating field arrays caused substantial surface dose enhancement and measurable dose attenuation during 6-megavolt photon irradiation.
Adjunctive hydrogen gas inhalation was associated with numerically fewer moderate toxicities and exploratory serum metabolomic changes during head and neck chemoradiotherapy.
An international Delphi panel approved a three-step acute radiation dermatitis tool integrating patient-reported symptoms and clinician assessment.
Dose-dependent linear energy transfer constraints aligned with published proton toxicity data better than fixed threshold approaches.
A case report linked high-dose Boswellia serrata use for radiation necrosis with reversible acute kidney injury.
Existing thyroid complication models showed moderate performance and frequent miscalibration in long-term head and neck cancer survivorship.
In 24 surgically confirmed cases, three radiomic features differed nominally between pure osteoradionecrosis and osteoradionecrosis with recurrence.
Preoperative radiotherapy was not associated with greater renal dysfunction after nephrectomy for retroperitoneal sarcoma during follow-up extending to 80 months.
Regional diffusion changes distinguished patients who developed contrast-enhancing brain lesions as early as six months after proton therapy.
Computed tomography-derived muscle measures ranked highly for toxicity and quality of life, but added little predictive value beyond established clinical factors.
In mice, ultrahigh dose-rate X-rays caused less early testicular damage than conventional irradiation, with protection linked to ferroptosis suppression.
Normal-tissue sparing with ultrahigh dose-rate radiotherapy remains conditional and cannot replace conformal dosimetry, organ-at-risk constraints, or rigorous quality assurance.
Risk-adapted esophagus-sparing radiotherapy maintained target coverage, with grade 3 esophagitis in only 1.25% of high-risk patients.
Bone marrow-sparing planning reduced pelvic marrow dose, but heterogeneous evidence did not confirm a consistent reduction in hematologic toxicity.
Circulating lymphocyte counts remained stable during brain radiotherapy without concurrent chemotherapy, consistent with low estimated blood and cervical lymph-node dose